Abstract
Chemotherapy-induced neuropathic pain (CINP) has a very high prevalence (between 50 and 80% of cases) negatively impacting the quality of life of patients and may lead to treatment discontinuation. Preventive or symptomatic treatments for CINP are generally ineffective, making it necessary to investigate new therapeutic approaches that prevent or improve these symptoms. In this sense, per…